Newly Identified T Cell Subset Could Improve Immunotherapy Outcomes

A team led by researchers from the University of Houston has identified a subset of T cells, dubbed CD8-fit, that could significantly enhance the effectiveness of T-cell immunotherapy for cancer patients. While T-cell immunotherapy has revolutionized cancer treatment, not all patients respond favorably to these therapies.

To help improve clinical outcomes, the researchers employed a technique called TIMING (Timelapse Imaging Microscopy in Nanowell Grids), which uses visual AI to evaluate cell behavior, movement, and cancer-killing ability.

"Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response," said Ali Rezvan, first author of the paper published in Nature Cancer.

By tracking interactions between individual T cells and tumor cells across thousands of cells and integrating the results with single-cell RNA sequencing data, the researchers discovered the CD8-fit cells. These cells possess a unique molecular signature that could predict durable patient outcomes to T-cell therapies.

"We profiled these cells using single-cell RNA sequencing to identify the CD8-fit molecular signature that could be used to predict durable patient outcomes to T-cell therapies and validated our findings with independent datasets," Rezvan explained.

Remarkably, the CD8-fit signature is present in pre-manufactured T cells, persists in patients post-infusion, and is associated with long-term positive clinical responses. The researchers believe these "fit" T cells could drive clinical benefits in other tumors, paving the way for more effective and personalized cancer treatments.